1. What Happened to NKMax?

NKMax entered rehabilitation in 2024 and received court approval for its rehabilitation plan in June 2025. Positive changes include a new majority shareholder, NKGen Biotech, Inc., and improved financials. However, its listing status remains uncertain, and uncertainties surrounding immunocell therapy development persist.

2. Positive Signals vs. Remaining Risks

  • Positive Signals:
    • Completion of rehabilitation and improved financial structure
    • NKGen Biotech, Inc.’s acquisition of management control
    • Stable growth of the immunodiagnostic kit business
    • High growth potential of immunocell therapy
  • Remaining Risks:
    • Uncertainty regarding listing status
    • Uncertainty surrounding clinical trial success and commercialization of immunocell therapy
    • Short-term profitability concerns due to high R&D costs

3. Investment Strategy?

Investing in NKMax presents both high growth potential and significant risks. Carefully consider the following before making an investment decision:

  • Progress of the rehabilitation plan implementation
  • Clinical trial results of immunocell therapy
  • Overseas expansion performance of the immunodiagnostic kit business
  • Decisions regarding listing status by the Korea Exchange

4. Your Investment Checklist

For a successful investment in NKMax, review this checklist:

  • ✔ Understand the current status of the rehabilitation plan
  • ✔ Check the progress of immunocell therapy clinical trials
  • ✔ Analyze the market competitiveness of immunodiagnostic kits
  • ✔ Continuously monitor the listing status